Figure 5. STK40 is amplified/mutated in various tumors and more strongly expressed in TNBC than in other subtypes of breast cancer.

(A) We queried the cBio Cancer Genomics Portal (http://cbioportal.org) [54, 55] to determine whether STK40 was altered in various types of cancer. The graph imported from cbioportal shows the cancer types in which STK40 alterations (cutoff ≥ 1%) have been identified (green: mutation; blue: deletion; red: amplification). The arrows indicate the breast cancer studies where STK40 alterations were found. CAN: DNA copy number alteration, BCCRC: breast cancer patient xenografts; NEPC: neuroendocrine prostate cancer; MPNST: malignant peripheral nerve sheath tumor; DESM: desmoplastic melanoma; PCPG: pheochromocytoma and paraganglioma; CTCL: cutaneous T-cell lymphoma; DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; MBC: metastatic breast cancer; HNC: head and neck cancer; GBM: glioblastoma multiforme; NSCLC: non-small cell lung cancer. (B) We analyzed STK40 expression in the various breast tumor subtypes of the TCGA cohort [80]. The values obtained for the relative quantification of RNA were log-transformed and are shown as box plots. Outliers are shown within each population studied (open circles). ^***P<0.001 (comparisons with TNBC).